GeNeuro (ENXTPA:GNRO) - Stock Price, News & Analysis

GNRO Stock Overview

A clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. More details

GNRO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue (€0)

Does not have a meaningful market cap (€2M)

Earnings have declined by 8.6% per year over past 5 years

+ 3 more risks

GeNeuro SA Competitors

IntegraGen

ENXTPA:ALINT

€3.1m

Quantum Genomics Société Anonyme

ENXTPA:ALQGC

€5.0m

TME Pharma

ENXTPA:ALTME

€6.1m

TheraVet

ENXTPA:ALVET

€321.2k

Price History & Performance

Summary of all time highs, changes and price drops for GeNeuro
Historical stock prices
Current Share Price	€0.061
52 Week High	€2.35
52 Week Low	€0.056
Beta	0.34
11 Month Change	-25.37%
3 Month Change	-23.31%
1 Year Change	-94.06%
33 Year Change	-98.27%
5 Year Change	-98.20%
Change since IPO	-99.50%

Recent updates

Breakeven On The Horizon For GeNeuro SA (EPA:GNRO)

Mar 14

Analysts Expect Breakeven For GeNeuro SA (EPA:GNRO) Before Long

Nov 28

Shareholder Returns

	GNRO	FR Biotechs	FR Market
7D	-11.8%	-7.7%	-0.3%
1Y	-94.1%	-26.4%	-3.5%

Return vs Industry: GNRO underperformed the French Biotechs industry which returned -26.4% over the past year.

Return vs Market: GNRO underperformed the French Market which returned -3.5% over the past year.

Price Volatility

Is GNRO's price volatile compared to industry and market?
GNRO volatility
GNRO Average Weekly Movement	17.8%
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.5%
10% most volatile stocks in FR Market	9.2%
10% least volatile stocks in FR Market	2.2%

Stable Share Price: GNRO's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: GNRO's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

Founded	Employees	CEO	Website
2006	17	Jesus Martin-Garcia	www.geneuro.com

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301.

GeNeuro SA Fundamentals Summary

How do GeNeuro's earnings and revenue compare to its market cap?
GNRO fundamental statistics
Market cap	€2.12m
Earnings (TTM)	-€14.76m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is GNRO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNRO income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€14.76m
Earnings	-€14.76m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.50
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-93.4%

How did GNRO perform over the long term?

See historical performance and comparison

GNRO Stock Overview

Risk Analysis

GeNeuro SA Competitors

ENXTPA:ALINT

€3.1m

ENXTPA:ALQGC

€5.0m

ENXTPA:ALTME

€6.1m

ENXTPA:ALVET

€321.2k

Price History & Performance

Recent News & Updates

New minor risk - Financial data availability

Price target decreased by 49% to €2.05

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

Geneuro SA Announces Appointments of Board of Directors

New minor risk - Shareholder dilution

Recent updates

New minor risk - Financial data availability

Price target decreased by 49% to €2.05

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

Geneuro SA Announces Appointments of Board of Directors

New minor risk - Shareholder dilution

GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.

Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

New major risk - Negative shareholders equity

New minor risk - Share price stability

GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients

GeNeuro SA to Report First Half, 2023 Results on Sep 29, 2023

New minor risk - Profitability

Insufficient new directors

GeNeuro SA, Annual General Meeting, Jun 14, 2023

Price target decreased to €5.55

Insufficient new directors

GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab

Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms

GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis

Geneuro Is Granted Authorization by the Swiss Health Authority to Initiate A Phase II Study Evaluating Temelimab in Patients with Severe Neuropsychiatric Post-Covid Syndromes

Price target decreased to €5.55

Insufficient new directors

GeNeuro SA, Annual General Meeting, May 31, 2022

GeNeuro and Fondamental Foundation Announce the First Results of the Collaboration for the Development of Diagnostic and Therapeutic Options for Patients with Post-Covid Neuropsychiatric Syndromes

GeNeuro Announces the Completion of Its ProTEct-MS Study and Confirms the March Timeline for Top-line Results

Geneuro Sa unveils Additional Results from the Preclinical Research Program in Amyotrophic Lateral Sclerosis (Als) Developed in Partnership with the National Institute of Neurological Disorders and Stroke

Geneuro Receives EUR 6.4 Million in Funding from the Swiss Government for the Development of Temelimab Against Long-Covid

GeNeuro Announces First Patient Having Finished the ProTEct-MS Study at the Karolinska Institutet’s Academic Specialist Center Has Entered the Study Extension

GeNeuro Announces the Publication in Multiple Sclerosis of Results From CHANGE-MS and ANGEL-MS Studies

Geneuro Presents Data Supporting Pathogenic Role of an Endogenous Retroviral Protein (HERV-W ENV) in Post-Covid Neuropsychiatric Syndrome

Consensus forecasts updated

Breakeven On The Horizon For GeNeuro SA (EPA:GNRO)

GeNeuro SA Announces Independent Drug Safety Monitoring Board (Dsmb) Has Concluded the Phase 2 Trial of Temelimab in Ms Patients

GeNeuro Completes Patient Recruitment in Temelimab Phase 2 Multiple Sclerosis Trial at the Karolinska Institutet’s Academic Specialist Center (ASC)

New 90-day high: €3.92

New 90-day low: €2.60

Analysts Expect Breakeven For GeNeuro SA (EPA:GNRO) Before Long

New 90-day low: €2.62

New 90-day low: €3.00

New 90-day low: €3.01

GeNeuro SA Announces Management Changes

GeNeuro SA to Report First Half, 2020 Results on Sep 29, 2020

Shareholder Returns

Price Volatility

About the Company

GeNeuro SA Fundamentals Summary

0.0x

-0.1x

Earnings & Revenue